GlassScriptPhysician profile
Inty Allen
NPI 1780194753
$5,683.82
in general payments reported to CMS, 2019-2025
10 companies · $52.70 in 2025
The $52.70 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $561 · 2022: $524 · 2023: $4,163 · 2024: $383 · 2025: $52.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,350 · Food and Beverage: $1,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,350.00 |
| Food and Beverage | $1,248.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,231.93 | 2021-2024 | |
| Novo Nordisk INC | $789.97 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $335.74 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $112.96 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $59.85 | 2022 | |
| Biogen, INC. | $52.70 | 2025 | Zurzuvae |
| Biohaven Pharmaceuticals, INC. | $47.28 | 2021 | |
| Pfizer INC. | $22.66 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $16.94 | 2023 | Farxiga |
| Amgen INC. | $13.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inty Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.